Predicting Outcome after Acute Basilar Artery Occlusion Based on Admission CharacteristicsAuthor Response:
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Editors' Note: In reference to “Predicting outcome after acute basilar artery occlusion based on admission characteristics” by Drs. Greving et al., Drs. He and Li argue against a 9-hour treatment window for intra-arterial therapy, against the use of recanalization as a predictor of outcome, and for the development of prediction models for different treatment strategies. The authors respond. Drs. Li et al. comment on the new American Academy of Neurology guideline on IV immunoglobulin (IVIg) for neuromuscular disorders, pointing out where evidence is still lacking on the use of IVIg in myasthenia gravis. Robert C. Griggs, MD, and Megan Alcauskas, MD
Greving et al. …
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
Alert Me
Recommended articles
-
Five New Things
Myasthenia gravisFive new thingsJeffrey M. Statland, Emma Ciafaloni et al.Neurology: Clinical Practice, April 15, 2013 -
Eye on Practice
An analysis of AAN′s evidence-based guideline for IVIg use in neurologic disordersProvider impact and payer perspectivesSaty Satya-Murti, Katie M. Shepard, Joel M. Kaufman et al.Neurology: Clinical Practice, June 11, 2012 -
Articles
Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitalsA. Alshekhlee, J. D. Miles, B. Katirji et al.Neurology, May 04, 2009 -
Special Article
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosisReport of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of NeurologyAlexander Rae-Grant, Gregory S. Day, Ruth Ann Marrie et al.Neurology, April 23, 2018